Analystreport

InnovAge (NASDAQ:INNV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

InnovAge Holding Corp.  (INNV) 
NASDAQ:AMEX Investor Relations: innovuspharma.com